Navigation Links
Lumenis Introduces Advanced Retinal Laser Delivery Technology at the 2009 American Academy of Ophthalmology Annual Meeting in San Francisco, California, USA
Date:10/27/2009

SANTA CLARA, Calif., Oct. 27 /PRNewswire/ -- Lumenis Ltd. a global developer, manufacturer and marketer of laser, light-based and radiofrequency devices for ophthalmic, surgical and aesthetic applications, announced today that it introduced a breakthrough ophthalmic laser delivery technology on October 24th at the American Academy of Ophthalmology (AAO) Annual Meeting in San Francisco, California, USA.

Dov Ofer, Lumenis' President and Chief Executive Officer stated: "Lumenis is proud to be yet again at the forefront of ophthalmic laser technology with the introduction of InSight®, a fully integrated, advanced retinal laser delivery technology and slit lamp bio-microscope. This achievement continues Lumenis' 40-year history of ophthalmic laser innovation. In 1970 we were the very first company to introduce a laser in this field; since then, we have followed with a series of additional sight-preserving milestones, including the first laser photocoagulator, laser indirect ophthalmoscope, multicolor photocoagulator, photodynamic (PDT) laser, the revolutionary Selective Laser Trabeculoplasty (SLT) system, and solid state multicolor laser."

"At this year's AAO Meeting, we continue this long-standing tradition as we proudly showcase the newest addition to our existing and already robust product portfolio of ophthalmic lasers and delivery devices. Our InSight represents the latest in retina visualization and laser delivery technology, and it successfully addresses some of the well-known challenges in ophthalmic laser delivery devices, namely, clear visualization of the retina and precise laser delivery to the target tissue," said Dov Ofer.

"We are very excited to significantly expand our capabilities in the Retina segment with the introduction of InSight," said Mr. Lloyd Diamond, Vice President & General Manager of Lumenis Vision, the ophthalmic business unit of Lumenis. "The InSight was designed to truly elevate performance and precision to new levels - allowing general ophthalmologists and retina specialists to customize each treatment and exercise complete control throughout the laser procedure. This ability is achieved through our unique and patented co-linear optical design, which projects both illumination and laser beam through the same pathway. Furthermore, the CoLin mechanism is controlled directly through InSight's integrated joystick, which also features our patented AcuGuide(TM) technology for fine movement and beam manipulation. With this technology, our customers can command complete control of the laser procedure literally with their fingertip."

"The InSight significantly facilitates laser delivery to the retina. Whether you are performing pan-retinal photocoagulation or a macular focal or grid laser treatment, the InSight provides you with complete control throughout the procedure, making the procedure easier for the treating physician," stated Dr. Pazit Pianka MD, an Ophthalmologist and Medical Director of Lumenis Vision.

In addition to incorporating the most advanced laser delivery and optics technology, ergonomic factors play a key role in the product design, as we recognize the tremendous benefit these represent to ophthalmologists and their patients. "The InSight is a valuable addition to the Lumenis ophthalmic product portfolio, further enhancing and protecting our global leadership position in the markets we serve," concluded Mr. Diamond.

About the American Academy of Ophthalmology and 2009 Annual Meeting

The American Academy of Ophthalmology is the largest national membership association of ophthalmologists, medical doctors who provide comprehensive eye care, including medical, surgical and optical care. More than 90 percent of practicing U.S. ophthalmologists are Academy members, and the Academy has more than 7,000 international members. The Academy's 113th Annual Meeting was held from October 24 to 27 in San Francisco, CA. The 2009 Annual Meeting program highlighted how technology advances are improving patient care. For more information about the AAO and Annual Meeting, log on to http://www.aao.org.

About Lumenis

Lumenis, the world's largest medical laser company, is a global developer, manufacturer and distributor of laser, light-based and radiofrequency devices for surgical, aesthetic and ophthalmic applications, with more than 800 employees worldwide. Lumenis has over 250 patents, over 75 FDA clearances, an installed base of over 80,000 systems and presence in over 100 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability. Consequently we are able to deliver premium value and service to our customers. Lumenis' name is derived from Latin meaning "Light of Life", highlighting the light which is the basis of our technologies used to enhance life. For more information about Lumenis and its products, please go to: www.lumenis.com.

Lumenis, its logo, VersaPulse , SlimLine and Slimline GI are trademarks or registered trademarks of the Lumenis Group of Companies.

Certain statements and information in this press release may be deemed to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "project" or other similar words, but are not the only way these statements are identified. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements may be found in our most recent Annual Report on Form 20-F, including the section therein entitled "Risk Factors", as well in our reports on Form 6-K, filed with the Securities and Exchange Commission.

    For further information contact:
    Michelle Maydan
    Director of Corporate Communications
    1-866-569-0597
    +972-4-959-9004
    e-mail: mmaydan@lumenis.com

SOURCE Lumenis Ltd.


'/>"/>
SOURCE Lumenis Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Lumenis(R) Introduces AcuPulse(TM) for Fractional Laser Treatments
2. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
3. Dr. Dello Russo Introduces the New EYE-Q Lasik
4. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
5. Wedgewood Introduces Refresh(TM) Exchange-Program: Free Exchange of Expired Veterinary Compounded Medications Solves Key Industry Problem
6. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
7. Thermo Fisher Scientific Introduces Breakthrough in RNA-Interference Technology
8. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
9. Siemens Introduces New Standard of Care for Breast Ultrasound
10. Perceptive Informatics Introduces Medical Imaging Methodology to Accelerate Development Decisions About Alzheimers Treatments
11. Quest Diagnostics Introduces First Commercial Laboratory Test for Identifying the H1N1 Swine Flu Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... July 24, 2017  Diplomat Pharmacy, Inc. (NYSE: ... its second quarter 2017 operating results on Monday, August ... to follow at 5:00 p.m. ET. ... to a live broadcast of the conference call by ... participant code 51641230 approximately 15 minutes prior to the ...
(Date:7/20/2017)... 2017  Prime Therapeutics LLC (Prime) released this statement from ... today,s Institute for Clinical and Economic Review,s (ICER) public ... and value of abuse-deterrent formulations (ADF) of opioids. Prime was ... the meeting. "The ... to the use of abuse-deterrent formulations (ADF) in opioids in ...
(Date:7/14/2017)... VEGAS , July 13, 2017 It should ... United States is in the midst of a ... Control , since 1999, the number of overdose deaths from ... "resulting in over half a million dead from 2001 to ... codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a compelling ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... 2017 , ... Patients with missing teeth now have the ... from Dr. Alejandro Kovacs. Dr. Kovacs is a board-certified periodontist and prosthodontist who ... dental implants in Longview, TX. , During traditional dental implant ...
(Date:7/27/2017)... ... 27, 2017 , ... TransPanel Volume 4 is a collection of animating panel ... exclusive features transitions that contain between 2 and 6 animated panels. Change the direction ... menus. TransPanel Volume 4 makes editing easy in Final Cut Pro X. , TransPanel ...
(Date:7/27/2017)... Clara, CA (PRWEB) , ... July 27, 2017 ... ... announces the addition of a secure cloud-based polysomnography (PSG) distributed scoring solution to ... support accelerated diagnostics and sleep care management. The speed and functionality of scoring ...
(Date:7/27/2017)... ... 2017 , ... SSCI, a division of Albany Molecular Research, ... representing a milestone achievement. , As an industry-leading provider of ... served as expert and fact witnesses to assist our clients to perform infringement ...
(Date:7/27/2017)... ... ... Angeles leg of the US movie premier of the Man in the Camo Jacket will ... Davis Theater inside the Grammy Museum Located in downtown Los Angeles in the LA Live ... musician, Mike Peters (of The Alarm), his rise to fame, battle with cancer and inspiring ...
Breaking Medicine News(10 mins):